UK's Bicycle Therapeutics Q2 net loss narrows on reduced clinical program expenses

Overview

• UK oncology drug developer's Q2 net loss narrowed from prior year

• Collaboration revenue for Q2 declined sharply year-over-year

• Lower operating expenses driven by reduced clinical program and personnel costs after workforce reduction

Outlook

• Company expects cash runway to extend into 2030

• Bicycle Therapeutics remains on track to begin BT1702 Phase 1 trial in 2027

• Company is actively enrolling patients in Phase 2 trial for nuzefatide in recurrent pancreatic cancer

Result Drivers

• LOWER CLINICAL AND PERSONNEL COSTS - Co said reduced clinical program expenses and workforce reduction drove lower RD and GA expenses

• OPERATIONAL SPENDING - Decrease in cash and cash equivalents was primarily due to cash used in operations, including clinical program activities

Company press release: ID:nBw5LzY5Ya

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology medical research peer group is "buy"

• Wall Street's median 12-month price target for Bicycle Therapeutics PLC is $12.00, about 210.9% above its July 29 closing price of $3.86

Reuters Recommended Reads

• July 28 - US FDA staff cast doubt on Replimune cancer drug's benefit; shares slide

• July 29 - Ionis Q2 adjusted operating loss narrows

• July 29 - Dyne Therapeutics reports larger-than-expected Q2 net loss per share

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)